Teva and Sanofi’s Ulcerative Colitis and Crohn’s Disease Drug Shows Promise in Phase 2b Trial
Promising Phase 2b results show Teva and Sanofi’s duvakitug achieved high remission rates in both ulcerative colitis and Crohn’s disease patients. This anti-TL1A antibody may offer a new treatment approach for these inflammatory bowel diseases.